X
[{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Diurnal Group"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Futura Medical"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Futura Medical has received official minutes from the US Food and Drug Administration (FDA) for MED3000, the Company’s breakthrough fast acting clinically proven treatment for erectile dysfunction.
Lead Product(s):
MED3000
Therapeutic Area: Endocrinology
Product Name: MED3000
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 22, 2021
Details:
The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.
Lead Product(s):
Hydrocortisone
Therapeutic Area: Endocrinology
Product Name: Undisclosed
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Eton Pharmaceuticals
Deal Size: $7.5 million
Upfront Cash: $3.5 million
Deal Type: Licensing Agreement
March 27, 2020